Efficacy of Serum Bovine Immunoglobulin in Improving Nutritional Status in Advanced COPD
A Randomized, Double Blinded, Placebo-controlled Pilot Study of Serum Bovine Immunoglobulin (SBI) for Cachexia in Patients With Advanced COPD
  • Phase

  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    serum bovine immunoglobulin ...
  • Study Participants

This study will evaluate the use of a medical food, oral serum-derived bovine immunoglobulin/protein isolate (SBI), in helping patients with advanced COPD with cachexia (a wasting syndrome) improve their nutritional status and gain weight. The medical food is in powder form and is mixed with a liquid such as water or orange juice and consumed by swallowing. The primary hypothesis is that SBI protein isolate (SBI) will improve the nutritional status of cachexic patients with advanced stages of COPD.
Study Started
Dec 31
Primary Completion
Apr 30
Last Update
Sep 02

Dietary Supplement Serum bovine immunoglobulin (SBI) medical food

Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.

Dietary Supplement Placebo (for serum bovine immunoglobulin)

inactive powder substance Placebo Comparator

inactive powder substance by mouth twice a day for 6 months

serum bovine immunoglobulin (SBI) medical food Experimental

SBI medical food 5 gr powder substance by mouth twice a day for 6 months

serum bovine immunoglobulin (SBI) medicalfood Experimental

SBI medical food 10 gr powder substance by mouth twice a day for 6 months


Inclusion Criteria:

Age between age 30 and 80 at Baseline Visit
Diagnosed with 2012 spirometric COPD GOLD Stage 3 (FEV1/FVC ratio <0.70, FEV1 30-49% of normal) or GOLD Stage 4 (FEV1/FVC <0.70, FEV1 <30% of normal or FEV1<50% of normal with chronic respiratory failure present)
Able to tolerate and willing to undergo study procedures
Body Mass Index below 21
Signed Informed Consent

Exclusion Criteria:

History of comorbid condition severe enough to significantly impact 6 months outcomes
Current substance abuse, including tobacco, alcohol and illicit drugs
Diagnosis of unstable cardiovascular disease including myocardial infarction in the past 6 weeks, uncontrolled congestive heart failure, or uncontrolled arrhythmia
Dementia or other cognitive dysfunction which in the opinion of the investigator would prevent the participant from consenting to the study or completing study procedures
Active pulmonary infection with tuberculosis
Non-COPD obstructive lung disease (various bronchiolitides, sarcoidosis, LAM, histiocytosis X) or parenchymal lung disease, pulmonary vascular disease, pleural disease, severe kyphoscoliosis, neuromuscular weakness, or other cardiovascular and pulmonary disease, that limit the interpretability of the pulmonary function measures
Prior significant difficulties with pulmonary function testing
Hypersensitivity to or intolerance of albuterol sulfate or ipratropium bromide or propellants or excipients of the inhalers, or to beef
History of lung or other organ transplant
Currently taking >20mg of prednisone or equivalent systemic corticosteroid
Currently taking any immunosuppressive agent
History of lung cancer or any cancer that spread to multiple locations in the body
Known HIV/AIDS infection
History of or current exposure to chemotherapy or radiation treatments that, in the opinion of the investigator, limits the interpretability of the pulmonary function measures.
Current or planned pregnancy within the study course.
Currently institutionalized (e.g., prisons, long-term care facilities)
No Results Posted